Single- and multiple-dose pharmacokinetics of oral creatine.
about
Creatine for treating muscle disordersCreatine for treating muscle disordersCreatine for treating muscle disordersCreatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?Comparison of new forms of creatine in raising plasma creatine levelsSex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in ratsTotal body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humansA review of creatine supplementation in age-related diseases: more than a supplement for athletes.Effects on Energy Metabolism of Two Guanidine Molecules, (Boc)2 -Creatine and Metformin.Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport.Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans.pH-dependent stability of creatine ethyl ester: relevance to oral absorptionCreatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells.The creatine content of Creatine Serum and the change in the plasma concentration with ingestion of a single dose.Creatine supplementation reduces doxorubicin-induced cardiomyocellular injury.AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes.Creatine supplementation: effects on blood creatine kinase activity responses to resistance exercise and creatine kinase activity measurement
P2860
Q24202243-DC59C00F-29C3-4449-ABAC-02434AFAD493Q24236598-F006DDFA-F761-4865-9548-43227FB57021Q24246414-A1DFBC53-A48D-437F-A4D2-12C0182E7BD4Q24631151-2B2C09F5-F749-483F-B227-A9BE90957949Q28257059-B1E0EBDF-2B72-4896-9F46-99583037CB78Q33771249-89C99546-C277-4F00-A67B-FC14B43DD310Q33781323-B2F3F282-A2B6-44DC-BACD-1C93A805CA2CQ35005568-2081C218-BEC2-4796-A49B-528AEDA4B421Q38719175-C42FA4CB-77EB-48C7-A355-44378A18FC4AQ39321477-4B25D8D8-8F62-40C7-86B4-BFCD90FAF290Q41473712-D198087B-5538-44DB-BF62-AFCFA7626B44Q42149011-097C4FC8-455B-4431-98C8-3C64129C515AQ42429592-269FB35F-F16B-4DC5-8EAD-768AD653199EQ42455552-039D291D-5947-4F89-AEC3-62BF5D46E56CQ45129461-BAD8C86B-DE4A-4950-ADD0-B3F60B872A71Q46834237-547A32B4-A5FF-4594-BA83-8CA597FCFC1DQ54608694-F17C643F-C4D2-44CD-950E-67B15E2E06B1Q57523648-B0544430-D932-4E41-B339-44D3B5E6CD54
P2860
Single- and multiple-dose pharmacokinetics of oral creatine.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Single- and multiple-dose pharmacokinetics of oral creatine.
@en
Single- and multiple-dose pharmacokinetics of oral creatine.
@nl
type
label
Single- and multiple-dose pharmacokinetics of oral creatine.
@en
Single- and multiple-dose pharmacokinetics of oral creatine.
@nl
prefLabel
Single- and multiple-dose pharmacokinetics of oral creatine.
@en
Single- and multiple-dose pharmacokinetics of oral creatine.
@nl
P2093
P2860
P356
P1476
Single- and multiple-dose pharmacokinetics of oral creatine
@en
P2093
Gayle A Brazeau
Hartmut Derendorf
Maria Grant
Markus Müller
P2860
P356
10.1177/0091270002239703
P577
2003-01-01T00:00:00Z